Repatha is a drug intended to treat patients with high cholesterol. The Pushotronex system offers a new, monthly single-dose administration option for the drug.
The device, created in conjunction with West Pharmaceutical Services in Exton, Pa., attaches to the body, allowing for hands-free administration.
The medicine may also be administered twice a week through the SureClick autoinjector.
Amgen, based in Thousand Oaks, Calif., expects the Pushtronex system to hit the market in early August.
More articles on supply chain:
Anti-HIV drug largely underused in San Francisco: 5 things to know
Drug monitoring programs show reduction in opioid overdoses: 6 things to know
FDA stops Juno’s cancer drug trials after 3 patients die
